The Latest Breaking News from Sanofi

France’s Economy Minister has warned that the government could block the sale of a subsidiary of the French pharmaceutical company Sanofi to a US private equity firm if it cannot guarantee that its production of paracetamol, under the name Doliprane, remains in France.

The planned sale of France's best-selling medical drug to US investors has caused the government a splitting headache after an outcry against the project from politicians on all sides.

France's Economy and Industry ministers, Antoine Armand and Marc Ferracci, are heading to Lisieux this Monday to visit the production sites of popular headache reliever Doliprane. The visit takes place after the maker of the pill, French pharma group Sanofi, said it was in talks to sell off its consumer…

Bioverativ formed a perfect double bottom, a key chart pattern for growth stock hunters, and broke out ahead of its big 61% gain on news it's being bought by Sanofi.

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.

We may think of air pollution as an outdoor problem, made up of car exhaust and smog. But if the air inside our homes is polluted, this can also affect our health.

Two flu vaccines are FDA-approved exclusively for people 65 and older, who are at higher risk of severe infection.

Officials say vaccination programme could prevent thousands of hospital admissions for babies

Shenzhen Component Index closed up 0.94%

Dr. Reddy's reported consolidated revenues of ₹7,673 crores (US$ 921 million) for Q1FY25, marking a 14% year-on-year increase and a 8% sequential growth.